期刊文献+

雄激素受体基因(CAG)n重复多态性长度对接受初始内分泌治疗的转移性前列腺癌患者预后的影响 被引量:2

Germline (CAG) n repeat length of androgen receptor among metastatic prostate cancer patients af-ter endocrine therapy
原文传递
导出
摘要 目的探讨雄激素受体(androgenreceptor,AR)基因(CAG)1"1重复多态性长度与接受初始内分泌治疗的转移性前列腺癌患者预后的关系。方法收集2006年1月至2012年1月接受初始内分泌治疗的转移性前列腺癌患者53例,诊断年龄45~87岁,中位年龄65岁。用PCR和直接测序方法对前列腺癌患者外周血标本进行(CAG)n重复多态性长度测定,结合临床资料分析(CAG)n重复多态性长度与生化无进展生存时间(biochemicalprogressionfreesurvival,bPFS)及总生存时间(overallsurvival,OS)的关系。结果(CAG)n重复多态性长度为14—32,中位长度为21。按(CAG)n中位长度分为(CAG)n≤21组33例和(CAG)n≥22组20例。中位随访36个月。Kaplan—Meier分析显示,与(CAG)n≥22组比较,(CAG)n≤21组患者的bPFS及OS均缩短,差异有统计学意义(P〈O.05)。(CAG)n重复多态性长度是影响转移性前列腺癌患者接受初始内分泌治疗的bPFS(HR2.820,95%C11.466~5.427,P=0.002)和OS(HR5.245,95%CI1.293~21.273,P=0.020)的独立预后因素。结论AR基因(CAG)n重复多态性长度可能影响转移性前列腺癌患者接受初始内分泌治疗的疗效;(CAG)n重复多态性长度≤21预示肿瘤预后不良。 Objective To investigate the clinical significance of (CAG)n repeats length of andro- gen receptor (AR) among the patients with metastatic prostate cancer (TNM1), and to analyze their rele- vance to survival. Methods This study retrospectively investigated fifty-three metastatic prostate cancer patients aged 65 years (range 45-87) who were initially treated with endocrine therapy. The length of the (CAG) n repeats of blood samples was determined by both PCR sequencing and fragment analysis. The clini- cal significance of (CAG)n repeats and its correlation with biochemical progression free survival (bPFS) and overall survival (OS) were investigated. Results The median length of CAG repeats was 21, ranged from 14 to 32. According to the median (CAG)n repeats length,two groups were divided as (CAG)n ≤ 21 and(CAG) n ≥ 22. The median follow-up was 36 months. Patients with (CAG)n ≤21 had significantly shor- ter OS and bPFS than those with (CAG)n≥ 22 (P 〈0.05). Shorter CAG repeats remained significant bPFS (HR 2.820, 95%C1 1.466-5.427, P=0.002) and OS (HR 5.245, 95%C1 1.293-21.27, P=0.020) pre- dictor in multivariate analysis. Conclusions The efficacy of endocrine therapy for metastatic prostatecancer patients maybe influenced by the AR-CAG repeats length, and short (CAG) n repeats predict bad prognosis.
出处 《中华泌尿外科杂志》 CAS CSCD 北大核心 2013年第12期901-905,共5页 Chinese Journal of Urology
基金 国家自然科学基金(81071787) 天津市应用基础及前沿技术研究计划(08JCYBJC05300)
关键词 CAG长度 雄激素受体 转移性前列腺癌 预后 去势治疗 CAG repeat length Androgen receptor Metastatic prostate cancer Prognosis Androgen deprivation therapy
  • 相关文献

参考文献19

  • 1Lonergan PE,Tindall DJ.Androgen receptor signaling in prostate cancer development and progression.J Carcinog,2011,10:20.
  • 2Montgomery JS,Price DK,Figg WD.The androgen receptor gene and its influence on the development and progression of prostate cancer..1 Pathol,2001,195:138-146.
  • 3Stanford JL,Just JJ,Gibbs M,et al.Polymorphic repeats in the androgen receptor gene:molecular markers of prostate cancer risk.Cancer Res,1997,57:1194-1198.
  • 4Suzuki H,Akakura K,Komiya A,et al.CAG polymorphic repeat lengths in androgen receptor gene among Japanese prostate cancer patients:potential predictor of prognosis after endocrine therapy.Prostate,2002,51:219-224.
  • 5Misra D,Xie W,Regan MM,et al.Germline CAG repeat length of the androgen receptor and time to progression in patients with prostate cancer treated with androgen deprivation therapy.BJU Int,2011,108:1086-1091.
  • 6古力米热,李鸿伟,王军起,龚侃,那彦群.维吾尔族前列腺癌与雄激素受体CAG重复多态性的关系[J].中华医学遗传学杂志,2004,21(4):415-416. 被引量:3
  • 7Hsing AW,Gao YT,Wu G,et al.Polymorphic CAG and GGN repeat lengths in the androgen receptor gene and prostate cancer risk:a population-based case-control study in China.Cancer Res,2000,60:5111-5116.
  • 8Pendleton JM,Tan WW,Anai S,et al.Phase Ⅱ trial of isoflavone in prostate-specific antigen recurrent prostate cancer after previous local therapy.BMC Cancer,2008,8:132.
  • 9余凯远,翁志梁,王思齐,余志贤,陈伟,吴秀玲,李澄棣.间歇性与持续性雄激素阻断治疗晚期前列腺癌疗效比较[J].中华泌尿外科杂志,2006,27(11):761-764. 被引量:31
  • 10Madjunkova S,Eftimov A,Georgicv V,et al.CAG repeat number in the androgen receptor gene and prostate cancer.Balkan J Med Genet,2012,15:31-36.

二级参考文献39

  • 1American Society of Clinical Oncology Recommendations for Initial hormornal Management of Androgen sensitive Meta static Recurrent, or Progressive Prostate Cancer. J Clin Oncol, 2004, 22: 2927-2941.
  • 2Saitoh H, Hida M, Shimbo T, et al. Metastatic patterns of prostatic cancer. Correlation between sites and number of or gans involved. Cancer, 1984, 54:3078-3084.
  • 3Bray F, Sankila R, Ferlar J, et al. Estimates of cancer inci dence and mortality in Europe in 1995. Eur J Cancer, 2002, 38: 99-166.
  • 4Catalona WJ, Richie JP, Ahmann FR, et al. Comparison of digital rectal examination and serum prostate specific antigen in the early detection of prostate cancer: results of a multi center clinical trial of 6630 men. J Urol, 1994, 151: 1283- 1290.
  • 5Prostate Cancer Trialists' Collaborative Group. Maximum androgen blockage in advanced prostate cancer. An overview of the randomized trials. Lancet, 2000, 355: 1491-1498.
  • 6Hsing AW, Chu LW, Stanczyk FZ. Androgen and prostate cancer: is the hypothesis dead? Cancer Epidemiol Biomarkers Prey, 2008, 17: 2525-2530.
  • 7Lane BR. Low testosterone and risk of biochemical recur fence and poorly differentiated prostate cancer at radical prostatectomy. Urology, 2008, 72: 1240-1245.
  • 8Isom Batz G, Bianco FJ Jc, Kattan MW, et al. Testosterone as a predictor of pathological stage in clinically localized pros tatecancer. J Urol, 2005, 173: 1935-1937.
  • 9Yamamoto S, Yonese J, Kawakami S, et al. Preoperative serum testosterone level as an independent predictor of treatment failure following radical prostatectomy. Eur Urol, 2007, 52: 696-701.
  • 10Furuya Y, Nozaki T, Nagakawa O, et al. Low serum testosterone level predicts worse response to endocrine therapy in Japanese patients withrnetastatie prostate cancer. Endocr J, 2002, 49: 85-90.

共引文献46

同被引文献15

引证文献2

二级引证文献5

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部